Mirati Presents Late-Breaking Results Evaluating Combination Of Adagrasib And Pembrolizumab In First-Line Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Mirati Therapeutics has presented late-breaking results evaluating the combination of Adagrasib and Pembrolizumab in first-line non-small cell lung cancer (NSCLC). The data shows a manageable safety profile and early signs of durability of Adagrasib in combination with a checkpoint inhibitor in the first-line NSCLC setting.
October 17, 2023 | 8:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive results from the combination of Adagrasib and Pembrolizumab in first-line NSCLC treatment could potentially boost Mirati Therapeutics' stock in the short term.
The positive results from the combination of Adagrasib and Pembrolizumab in first-line NSCLC treatment could potentially boost Mirati Therapeutics' stock in the short term. This is because successful clinical trials often lead to increased investor confidence and potential regulatory approval, which can drive up a company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100